Cardiovascular Field Launch Specialist (Remote)

Cytokinetics; United States; Remote; USD 162,000 - 195,000; Full time

Benefits offered by this job

Stock options

401k matching

Health insurance

Wellness stipends

Paid time off

Job summary

Cytokinetics is launching a novel cardiac myosin inhibitor for Hypertrophic Cardiomyopathy in the United States. You will drive sales in your territory, building strong relationships with IDNs, hospitals, cardiology clinics, and specialty pharmacies.

You will partner with internal teams to craft territory plans, deliver compelling clinical information, and support patient access. This role requires 5+ years in biotech/pharma sales and a willingness to travel up to 75%.

Qualifications

• Bachelor's degree required and progress in cardiology or rare disease is a plus.
• Minimum 5+ years in biotech/pharma sales with territory ownership.
• Experience with complex accounts, stakeholders, and patient needs.
• Knowledge of key cardiology accounts and market trends is preferred.

Responsibilities

• Deliver sales results and be the accountable owner for launch in territory.
• Develop territory plans with cross-functional teams to meet customer needs.
• Serve as SME and resource delivering disease and product information.
• Communicate resources and payer information to healthcare professionals.

Skills

Territory ownership

Clinical acumen

Biotech/pharma sales

Cardiology exposure

Specialty product launch

KOL knowledge

Key accounts

Strategic planning

Travel readiness

Education

Bachelor's degree

Job description

Cytokinetics is launching a novel cardiac myosin inhibitor for Hypertrophic Cardiomyopathy in the United States. You will drive sales in your territory, building strong relationships with IDNs, hospitals, cardiology clinics, and specialty pharmacies.

You will partner with internal teams to craft territory plans, deliver compelling clinical information, and support patient access. This role requires 5+ years in biotech/pharma sales and a willingness to travel up to 75%.